Revolution Biomanufacturing

Executive Summary

Revolution Biomanufacturing Inc. is a U.S.-based contract development and manufacturing organization (CDMO) specializing in scalable, end-to-end biomanufacturing for mRNA, cell, and gene therapies. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company leverages its process science expertise and cGMP-compliant facility to support clients from preclinical development through commercial-scale production. With the increasing demand for advanced therapies, Revolution Biomanufacturing is well-positioned to capitalize on the outsourcing trend by offering flexible, high-quality manufacturing solutions. The company's focus on personalized medicine and its integrated regulatory strategy enable it to accelerate time-to-market for its partners, addressing a critical bottleneck in the biotech industry. While the company is still privately held and lacks disclosed funding rounds, its operational facility and strategic location near major biotech hubs provide a strong foundation for growth. The absence of publicly announced partnerships or pipeline programs limits visibility, but the underlying market tailwinds in cell and gene therapy manufacturing remain robust.

Upcoming Catalysts (preview)

• Q3 2026FDA inspection of cGMP facility with successful outcome75% success
• Q4 2026Announcement of first major client partnership for commercial-scale manufacturing50% success
• TBDCapacity expansion or new technology platform launch (e.g., automated cell therapy manufacturing)40% success